Available data suggest that obtaining adequate sleep is associated with a better ability of the body to use carbohydrates as a source of energy and a lower risk of developing diabetes. The sleeping pill, Eszopiclone (Lunesta), has been approved by the Food and Drug Administration for the treatment of people who complain of trouble falling or staying asleep. This study will examine the hypothesis that the use of Eszopiclone (Lunesta) to improve the sleep of people with insomnia may also improve the use of sugar in their body.
Study participants will complete a set of oral and intravenous glucose (sugar) tolerance tests, which will be performed on two separate occasions in random order: once after a week of treatment with Eszopiclone (Lunesta) and once again after a week of receiving placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
20
Eszopiclone 3 mg by mouth daily at bedtime for 9 days
Placebo by mouth daily at bedtime for 9 days
University of Chicago
Chicago, Illinois, United States
Plasma Glucose Level at the 120-minute Time Point of a 75g Oral Glucose Tolerance Test
Time frame: at the end of each treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.